| Prev Close | 19.47 |
| Day Low/High | 19.20 / 19.95 |
| 52 Wk Low/High | 9.44 / 22.39 |
| Avg Volume | 1.40M |
Latest News
What Goes Up: Cramer's 'Mad Money' Recap (Wednesday 5/1/19)
Jim Cramer says it's not 1987 or 1999, and there's no reason to dump stocks right now, but he does advocate discipline and caution.
Kohl's, Exxon Mobil, Delta Air Lines: 'Mad Money' Lightning Round
Jim Cramer weighs in on Kohl's, Exxon Mobil, Delta Air Lines, Allergan, Arrowhead Research, Wayfair, Varonis Systems and more.
Arrowhead Pharmaceuticals To Webcast Fiscal 2019 Second Quarter Results
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 8, 2019, at 4:30 p.
Arrowhead Begins Triple Combination Cohort In Chronic HBV Patients And Earns $25 Million Milestone Payment From Janssen
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has begun dosing in a new triple combination cohort (cohort 12) that includes JNJ-3989 (formerly ARO-HBV) and additional undisclosed agents selected by Janssen Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Receives FDA Clearance To Begin Phase 2/3 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received clearance from the U.
Arrowhead Presents Clinical Data On JNJ-3989 (ARO-HBV) At The International Liver Congress™
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the presentation of clinical data from an ongoing Phase 1/2 study (AROHBV1001) of JNJ-3989 (formerly ARO-HBV), a third-generation subcutaneously administered RNA interference (RNAi)...
Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents And Reverses Alpha-1 Liver Disease At The International Liver Congress™
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at The International Liver Congress™ 2019 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), demonstrating that sustained reduction of...
Interesting ARWR Put And Call Options For May 17th
Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new May 17th contracts and identified one put and one call contract of particular interest.
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 22, 2018, the Compensation Committee of the Board of Directors approved "inducement" grants to 7 new employees under...
Arrowhead Pharmaceuticals Files IND For Pivotal Phase 2/3 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.
Arrowhead Pharmaceuticals Begins Dosing In Phase 1 Study Of ARO-APOC3 For Treatment Of Hypertriglyceridemia
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed for the treatment...
Arrowhead Pharmaceuticals To Present At Upcoming March 2019 Conferences
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: Barclays Global Healthcare Conference 2019 - Miami, March 12-14, 2019 March 12, 4:20 p.
Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 first quarter ended December 31, 2018.
Interesting ARWR Put And Call Options For September 20th
Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the September 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Arrowhead Pharmaceuticals To Webcast Fiscal 2019 First Quarter Results
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 7, 2019, at 4:30 p.
Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-APOC3 For Treatment Of Hypertriglyceridemia
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed...
Arrowhead Pharmaceuticals Begins Dosing In Phase 1 Study Of ARO-ANG3 For Treatment Of Dyslipidemias And Metabolic Diseases
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 (ANGPTL3) being developed for the...
First Week Of ARWR February 15th Options Trading
Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new February 15th contracts and identified one put and one call contract of particular interest.
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 7, 2018, the Board of Directors approved "inducement" grants to 3 new employees under Rule 5635(c)(4) of the...
Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 fourth quarter and year ended September 30, 2018.
Arrowhead Pharmaceuticals To Webcast 2018 Fiscal Year End Results
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on December 11, 2018, at 4:30 p.
Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data On ARO-AAT At Liver Meeting® 2018
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced clinical data from a Phase 1 study of ARO-AAT, the company's second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic...
Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data On ARO-HBV At Liver Meeting® 2018
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced preliminary clinical data from a Phase 1/2 study (AROHBV1001) of ARO-HBV, a third-generation subcutaneously administered RNA interference (RNAi) therapeutic candidate being developed as a...
Arrowhead Pharmaceuticals To Present At Upcoming November 2018 Conferences
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: BIT's 16th Annual Congress of International Drug Discovery Science and Technology - Jinan, China, November 6-8, 2018 November...
Arrowhead Pharmaceuticals Announces Closing Of Agreements With Janssen
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the license agreement and research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc.
First Week Of ARWR June 2019 Options Trading
Investors in Arrowhead Pharmaceuticals Inc saw new options become available this week, for the June 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
This Market Needs More Fear: Cramer's 'Mad Money' Recap (Thursday 10/18/18)
Jim Cramer says there's still too much greed and complacency, and not enough fear and panic.
AT&T, Arrowhead Research, 3M: 'Mad Money' Lightning Round
Jim Cramer takes a look at AT&T, Arrowhead Research, 3M, HollyFrontier, Brinker International, Viper Energy Partners and more.
